Conference Coverage

Avoiding in-hospital acute kidney injury is a new imperative


 

EXPERT ANALYSIS FROM ACP INTERNAL MECICINE


“These are highly toxic drugs to the kidney and we shouldn’t be using them,” Dr. Szerlip said.

He reported receiving research grants from LaJolla, Bayer, Akebia, and BioPorto, serving on a speakers’ bureau for Astute Medical, and acting as a consultant to Zs Pharma, Amarin, and LaJolla.

Pages

Recommended Reading

Low vitamin D levels linked to increased ESRD risk in SLE patients
MDedge Internal Medicine
Bicarb, acetylcysteine during angiography don’t protect kidneys
MDedge Internal Medicine
Intense urine output monitoring beneficial in ICU
MDedge Internal Medicine
Acute kidney injury linked with doubled inpatient VTEs
MDedge Internal Medicine
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
MDedge Internal Medicine
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
MDedge Internal Medicine
Can case management cut hypertension’s consequences?
MDedge Internal Medicine
Clearer picture emerging of renal impact of SGLT2s
MDedge Internal Medicine
Impaired kidney function no problem for dabigatran reversal
MDedge Internal Medicine
MDedge Daily News: Which nonopioids are ripe for abuse?
MDedge Internal Medicine